1.The Radiation Dose Absorbed by Healthy Parenchyma Is a Predictor for the Rate of Contralateral Hypertrophy After Unilobar Radioembolization of the Right Liver
Nazim COSKUN ; Aslihan YILDIRIM ; Alptug Ozer YUKSEL ; Murat CANYIGIT ; Elif OZDEMIR
Nuclear Medicine and Molecular Imaging 2022;56(6):291-298
Purpose:
To investigate the predictors of contralateral hypertrophy in patients treated with unilobar transarterial radioembolization (TARE) with yttrium-90-loaded resin microspheres due to unresectable right-liver tumors.
Methods:
Patients who underwent right unilobar TARE with resin microspheres between May 2019 and September 2021 were screened retrospectively. Contralateral hypertrophy was evaluated by calculating the kinetic growth rate (KGR) in 8–10 weeks after TARE. The predictors of increased KGR were determined with linear regression analysis.
Results:
A total of 24 patients (16 with primary and 8 with metastatic liver tumors) were included in the study. After right unilobar TARE, mean volume of the left lobe increased from 368.26 to 436.16 mL, while the mean volume of the right lobe decreased from 1576.22 to 1477.89 mL. The median KGR of the left lobe was 0.28% per week. The radiation dose absorbed by the healthy parenchyma of the right lobe was significantly higher in patients with increased KGR (31.62 vs. 18.78 Gy, p = 0.037). Linear regression analysis showed that the dose absorbed by healthy parenchyma was significantly associated with increased KGR (b = 0.014, p = 0.043).
Conclusion
Patients who received right unilobar TARE for liver malignancies could develop a substantial contralateral hypertrophy, and the radiation dose absorbed by the healthy parenchyma of the right lobe was significantly associated with increased KGR in the left lobe. TARE could have a role for inducing contralateral hypertrophy as it offers the advantage of concurrent local tumor control along with its hypertrophic effect.
2.Erratum: How will surface treatments affect the translucency of porcelain laminate veneers?.
Sedanur TURGUT ; Bora BAGIS ; Elif Aydogan AYAZ ; Fatih Mehmet KORKMAZ ; Kivanc Utku ULUSOY ; Yildirim Hakan BAGIS
The Journal of Advanced Prosthodontics 2014;6(2):150-150
There are some corrections in the body of the article.
3.How will surface treatments affect the translucency of porcelain laminate veneers?.
Sedanur TURGUT ; Bora BAGIS ; Elif Aydogan AYAZ ; Fatih Mehmet KORKMAZ ; Kivanc Utku ULUSOY ; Yildirim Hakan BAGIS
The Journal of Advanced Prosthodontics 2014;6(1):8-13
PURPOSE: The purpose of this study was to evaluate whether surface treatments affect the translucency of laminate veneers with different shades and thicknesses. MATERIALS AND METHODS: A total of 224 disc-shaped ceramic veneers were prepared from A1, A3, HT (High Translucent) and HO (High Opaque) shades of IPS e.max Press (Ivoclar Vivadent) with 0.5 mm and 1.0 mm thicknesses. The ceramics were divided into four groups for surface treatments. Group C: no surface treatments; Group HF: etched with hydrofluoric acid; Group SB: sandblasted with 50-microm Al2O3; and Group L; irradiated with an Er;YAG laser. A translucent shade of resin cement (Rely X Veneer, 3M ESPE) was chosen for cementation. The color values of the veneers were measured with a colorimeter and translucency parameter (TP) values were calculated. A three-way ANOVA with interactions for TP values was performed and Bonferroni tests were used when appropriate (alpha=0.05). RESULTS: There were significant interactions between the surface treatments, ceramic shades and thicknesses (P=.001). For the 0.5-mm-thick specimens there were significant differences after the SB and L treatments. There was no significant difference between the HF and C treatments for any shades or thicknesses (P>.05). For the 1-mm-thick ceramics, there was only a significant difference between the L and C treatments for the HT shade ceramics (P=.01). There were also significant differences between the SB and C treatments except not for the HO shades (P=.768). CONCLUSION: The SB and L treatments caused laminate veneers to become more opaque; however, HF treatment did not affect the TP values. When the laminate veneers were thinner, both the shade of the ceramic and the SB and laser treatments had a greater effect on the TP values.
Cementation
;
Ceramics
;
Dental Porcelain*
;
Hydrofluoric Acid
;
Resin Cements
4.Hot-Clot Artifacts in the Lung Parenchyma on F-18 Fluorodeoxyglucose Positron Emission Tomography/CT due to Faulty Injection Techniques: Two Case Reports.
Elif OZDEMIR ; Nilufer Yildirim POYRAZ ; Mutlay KESKIN ; Zuhal KANDEMIR ; Seyda TURKOLMEZ
Korean Journal of Radiology 2014;15(4):530-533
F-18-fluorodeoxyglucose (FDG) positron emission tomography/CT is an important whole-body imaging tool in the oncology and widely utilized to stage and restage various malignancies. The findings of significant focal accumulation of FDG in the lung parenchyma in the absence of corresponding CT abnormalities are related to the lung microembolism and known as hot-clot artifacts. Herein we present two cases with focal FDG uptake in the lung parenchyma with no structural lesions on the CT scan and discuss the possible mechanisms.
*Artifacts
;
False Positive Reactions
;
Female
;
Fluorodeoxyglucose F18/*administration & dosage/diagnostic use/pharmacokinetics
;
Humans
;
Lung/metabolism/radiography/*radionuclide imaging
;
Male
;
Middle Aged
;
Multimodal Imaging/methods
;
Positron-Emission Tomography/*methods
;
Pulmonary Embolism/radiography/*radionuclide imaging
;
Radiopharmaceuticals/*administration & dosage/diagnostic use/pharmacokinetics
;
Tomography, X-Ray Computed/methods
;
Young Adult
5.Is Obesity a Potential Risk factor for Poor Prognosis of COVID-19?
Meltem AGCA ; Eylem TUNCAY ; Elif YILDIRIM ; Reyhan YILDIZ ; Tülin SEVIM ; Dilek ERNAM ; Nermin Ozer YILMAZ ; Nazlı Huma TEKE ; Simge YAVUZ ; Zuhal KARAKURT ; ; Ipek OZMEN
Infection and Chemotherapy 2021;53(2):319-331
Background:
Coronavirus disease 2019 (COVID-19) continues to cause major mortality and morbidity worldwide even after a year of its emergence. In its early days, hypertension, diabetes, and cardiovascular diseases were noted as poor prognostic factors, while obesity gained attention at a later stage. In the present study, unfavorable clinical outcomes (transfer to the intensive care unit, invasive mechanical ventilation, and mortality) were investigated in obese patients with COVID-19.
Materials and Methods:
In this retrospective study we analyzed patients with positive polymerase chain reaction test in tertiary care hospital between March-May 2020. They were divided into 3 groups according to body mass index (BMI) as normal, overweight, and obese (BMI: 18.5 - 24.99 kg/m2 , 25 - 29.99 kg/m2 , and ≥ 30 kg/m2 , respectively). We compared clinical features and laboratory findings of these groups and recorded adverse clinical outcomes. Multivariate logistic analysis was performed for unfavorable outcomes.
Results:
There were 99 patients (35%), 116 (41%), and 69 patients (24%) in the normal-weight, overweight, and obese group, respectively. Among all patients, 52 (18%) patients were transferred to the intensive care unit (ICU), 30 (11%) patients received invasive mechanical ventilation (IMV), and 22 patients (8%) died. Obese patients had minimum 1 more comorbidity than normal BMI patients (73% vs. 50%, P = 0.002), and a longer median (interquartile range [IQR]) duration of hospitalization (8 [5 - 12] vs. 6 [5 - 9]) days, P = 0.006). Obese participants had higher concentrations of serum C-reactive protein, procalcitonin, ferritin than nonobese patients (P <0.05 in all). In a multivariate analysis, obesity was associated with ICU admission (adjusted odds ratio [aOR]: 2.99, 95% confidence interval [CI]: 1.26 - 7.04, P = 0.012). Moreover, IMV requirement was associated with obesity (aOR: 8.73, 95% CI: 2.44 - 31.20, P = 0.001). Mortality occurred in 16%, 9%, and 1% of the obese group, overweight group, and normal-weight group, respectively (Chi-square trend analysis, P = 0.002).
Conclusion
Obesity is a risk factor for adverse outcomes and caused increased mortality, hence requiring close follow-up.
6.Is Obesity a Potential Risk factor for Poor Prognosis of COVID-19?
Meltem AGCA ; Eylem TUNCAY ; Elif YILDIRIM ; Reyhan YILDIZ ; Tülin SEVIM ; Dilek ERNAM ; Nermin Ozer YILMAZ ; Nazlı Huma TEKE ; Simge YAVUZ ; Zuhal KARAKURT ; ; Ipek OZMEN
Infection and Chemotherapy 2021;53(2):319-331
Background:
Coronavirus disease 2019 (COVID-19) continues to cause major mortality and morbidity worldwide even after a year of its emergence. In its early days, hypertension, diabetes, and cardiovascular diseases were noted as poor prognostic factors, while obesity gained attention at a later stage. In the present study, unfavorable clinical outcomes (transfer to the intensive care unit, invasive mechanical ventilation, and mortality) were investigated in obese patients with COVID-19.
Materials and Methods:
In this retrospective study we analyzed patients with positive polymerase chain reaction test in tertiary care hospital between March-May 2020. They were divided into 3 groups according to body mass index (BMI) as normal, overweight, and obese (BMI: 18.5 - 24.99 kg/m2 , 25 - 29.99 kg/m2 , and ≥ 30 kg/m2 , respectively). We compared clinical features and laboratory findings of these groups and recorded adverse clinical outcomes. Multivariate logistic analysis was performed for unfavorable outcomes.
Results:
There were 99 patients (35%), 116 (41%), and 69 patients (24%) in the normal-weight, overweight, and obese group, respectively. Among all patients, 52 (18%) patients were transferred to the intensive care unit (ICU), 30 (11%) patients received invasive mechanical ventilation (IMV), and 22 patients (8%) died. Obese patients had minimum 1 more comorbidity than normal BMI patients (73% vs. 50%, P = 0.002), and a longer median (interquartile range [IQR]) duration of hospitalization (8 [5 - 12] vs. 6 [5 - 9]) days, P = 0.006). Obese participants had higher concentrations of serum C-reactive protein, procalcitonin, ferritin than nonobese patients (P <0.05 in all). In a multivariate analysis, obesity was associated with ICU admission (adjusted odds ratio [aOR]: 2.99, 95% confidence interval [CI]: 1.26 - 7.04, P = 0.012). Moreover, IMV requirement was associated with obesity (aOR: 8.73, 95% CI: 2.44 - 31.20, P = 0.001). Mortality occurred in 16%, 9%, and 1% of the obese group, overweight group, and normal-weight group, respectively (Chi-square trend analysis, P = 0.002).
Conclusion
Obesity is a risk factor for adverse outcomes and caused increased mortality, hence requiring close follow-up.